In this article
The photobiomodulation (PBM) wavelengths most people know — 630nm, 660nm, 810nm, 850nm — all fall within the so-called “optical window” of biological tissue, where absorption by haemoglobin, water, and melanin is relatively low. Step beyond 1000nm and you enter different territory. The 1060–1064nm range sits outside the standard PBM window, closer to where water absorption begins to rise significantly. Yet this wavelength range has carved out a distinct clinical niche, primarily in laser-based fat reduction and specific surgical applications.
This article examines what 1060nm and 1064nm actually do in biological tissue, how they differ from conventional red and near-infrared PBM, the clinical evidence behind their applications, and whether consumer devices at these wavelengths have any meaningful role.
The Physics: Why 1060nm Is Different
Absorption Characteristics
The optical properties of tissue change substantially as wavelength increases beyond 1000nm. At 850nm — the standard near-infrared PBM wavelength — water absorption is still very low. By 1060nm, water absorption has increased approximately tenfold compared to 850nm, though it remains far below the massive absorption peaks at 1450nm and 1940nm (Hale & Querry, 1973; cited in Jacques, 2013; PMID: 23208200).
This increased water absorption has two important consequences:
-
Reduced penetration depth. Light at 1060nm does not travel as far through tissue as 850nm light. The effective penetration depth is roughly 2–4mm in soft tissue, compared to 5–10mm or more for 850nm. This limits its utility for deep tissue PBM applications.
-
Thermal effects become relevant. Because water absorbs more energy at 1060nm, tissues containing water (which is essentially all biological tissue) convert more of the light energy into heat. At sufficient power densities, this creates a controlled thermal effect — the basis of several clinical applications.
Cytochrome c Oxidase Interaction
The primary photoacceptor for PBM — cytochrome c oxidase (CCO) in the mitochondrial electron transport chain — has absorption peaks in the red (around 620–680nm) and near-infrared (around 760–900nm) ranges (Karu, 2005; PMID: 16007521). At 1060nm, CCO absorption is negligible. This means 1060nm light does not stimulate mitochondrial ATP production through the same mechanism as conventional PBM wavelengths.
Any biological effects at 1060nm operate through different pathways: primarily thermal mechanisms, and potentially through interaction with water molecules and lipids rather than mitochondrial chromophores.
1064nm: The Nd:YAG Wavelength
Historical Significance
1064nm has a special status in medical laser physics. It is the fundamental emission wavelength of the neodymium-doped yttrium aluminium garnet (Nd:YAG) laser, one of the most widely used medical laser systems. Developed in the 1960s, the Nd:YAG laser has been used for decades in ophthalmology, dermatology, dentistry, and surgery (Peng et al., 2008; PMID: 18688659).
The Nd:YAG laser at 1064nm can penetrate deeper than many other medical lasers because, whilst water absorption is elevated relative to 850nm, it is still low enough to allow meaningful tissue penetration — particularly compared to CO₂ lasers (10,600nm) or erbium lasers (2,940nm), which are absorbed almost entirely within the first fraction of a millimetre.
Medical Applications of 1064nm Nd:YAG
Dermatology: 1064nm Nd:YAG lasers are used for laser hair removal (particularly effective on darker skin tones because 1064nm is less absorbed by melanin than shorter wavelengths), vascular lesion treatment, and tattoo removal (particularly dark inks) (Lanigan, 2003; PMID: 12654197).
Ophthalmology: YAG laser capsulotomy — using a Q-switched 1064nm laser to treat posterior capsule opacification after cataract surgery — is one of the most common ophthalmic laser procedures worldwide (Burq & Taqui, 2008; PMID: 19086737).
Dentistry: 1064nm lasers are used for soft tissue surgery, bacterial reduction in periodontal pockets, and endodontic disinfection (The et al., 2007; cited in research literature).
These are all laser-based applications using focused, high-power beams. They are fundamentally different from LED-based PBM in both mechanism and intent.
Fat Reduction: The Primary Clinical Application
SculpSure (1060nm Diode Laser)
The most commercially significant application of the 1060nm wavelength is SculpSure (Cynosure/Hologic), an FDA-cleared laser device for non-invasive fat reduction. SculpSure uses 1060nm diode lasers to heat subcutaneous adipose tissue to 42–47°C, causing thermal damage to adipocytes (fat cells) without damaging the overlying skin (Bass & Doherty, 2018; PMID: 29359790).
The mechanism is distinct from PBM:
- Hyperthermic lipolysis: The 1060nm wavelength is preferentially absorbed by fat tissue (lipids absorb more at this wavelength relative to water compared to shorter wavelengths), allowing selective heating of the fat layer
- Contact cooling: The device simultaneously cools the skin surface to prevent burns, creating a temperature differential where the subcutaneous fat is heated while the epidermis remains protected
- Apoptotic cell death: Fat cells heated to the target range undergo apoptosis (programmed cell death) over the following weeks. The body’s lymphatic system then clears the destroyed cells
- Gradual results: Clinical effects develop over 6–12 weeks post-treatment as the body processes and removes the damaged adipocytes
Clinical Evidence for 1060nm Fat Reduction
Bass and Doherty (2018; PMID: 29359790) published a multi-site study of SculpSure for fat reduction in the flanks and abdomen, reporting an average of 11% fat layer reduction measured by ultrasound at 12 weeks post-treatment. Patient satisfaction rates were high, and adverse events were limited to transient tenderness and mild swelling.
Katz et al. (2017; PMID: 28493418) demonstrated histological evidence of adipocyte destruction following 1060nm laser treatment, confirming the mechanism of action at the cellular level. Biopsy specimens showed disrupted adipocyte membranes and inflammatory cell infiltration consistent with thermal injury and subsequent apoptosis.
Decorato et al. (2017; PMID: 28617359) reported average fat layer reductions of 15–24% in submental (under-chin) fat treatment using 1060nm, with MRI measurements confirming the reduction.
Important Caveats
1060nm fat reduction is a clinical procedure, not a home treatment. The devices cost tens of thousands of pounds, require professional operation, and deliver controlled, high-power laser energy. The treatment involves significant discomfort during the heating phase and carries risks of burns if improperly administered.
The fat reduction is also modest in absolute terms. Patients losing 11–24% of their fat layer in a treated area may see visible improvement, but this is not comparable to surgical liposuction. SculpSure and similar devices are positioned as body contouring treatments for patients near their target weight, not as weight loss solutions.
Low-Level Laser Therapy (LLLT) at 1060nm
How It Differs from SculpSure
Some confusion exists between high-power 1060nm laser fat reduction (SculpSure) and low-level laser therapy for fat loss (devices like Zerona, which uses 635nm). These are entirely different approaches:
| Parameter | SculpSure (1060nm) | LLLT Fat Loss (e.g., Zerona at 635nm) |
|---|---|---|
| Mechanism | Thermal destruction of fat cells | Proposed pore formation in adipocyte membranes (non-thermal) |
| Power | High (clinical laser) | Low (cold laser) |
| Temperature change | Significant (42–47°C in fat layer) | Negligible |
| Fat cell fate | Apoptosis (cell death) | Cells remain viable (fat released, not destroyed) |
| Evidence quality | Multiple RCTs with imaging confirmation | Limited and contested |
| Availability | Clinical only | Clinical and some home devices |
The LLLT approach to fat loss typically uses visible red light (635nm), not 1060nm. The proposed mechanism — that low-level laser creates transient pores in adipocyte membranes, allowing stored lipids to leak out (Jackson et al., 2009; PMID: 19585346) — remains controversial and is not directly relevant to the 1060nm wavelength.
Consumer Devices at 1060nm: Do They Exist?
Current Market Reality
As of 2026, consumer LED panels operating at 1060nm are extremely rare. The standard wavelengths in consumer PBM devices are 630nm, 660nm, 810nm, 830nm, 850nm, and occasionally 940nm. There are practical reasons for this:
- LED availability: LEDs at 1060nm are less commonly manufactured for the PBM market. The demand is driven primarily by industrial and telecommunications applications (fibre optics operate near 1060nm), not health devices.
- Limited PBM rationale: Since 1060nm does not significantly activate cytochrome c oxidase, the theoretical basis for using it in a low-power LED panel is weak. The fat reduction applications require high-power laser energy that an LED panel cannot deliver.
- Water absorption concerns: The increased water absorption at 1060nm means more energy is converted to heat at the tissue surface, reducing the depth of penetration that makes near-infrared PBM useful.
A few multi-wavelength panels include 1060nm LEDs as part of a 5- or 6-wavelength configuration. PlatinumLED’s BIO series, for example, has offered configurations including wavelengths beyond 1000nm. However, the clinical evidence supporting the inclusion of 1060nm in a low-power LED panel is essentially non-existent. No published study has demonstrated PBM-type benefits from LED-delivered 1060nm light at the irradiance levels these panels produce.
Should You Seek Out 1060nm in a Panel?
For standard PBM applications — skin health, pain relief, muscle recovery, joint inflammation — there is no published evidence that 1060nm adds meaningful benefit beyond what 660nm and 850nm provide. The wavelengths with the strongest evidence base remain within the established optical window.
If your interest is fat reduction, the evidence supports clinical-grade 1060nm laser devices (SculpSure), not consumer LED panels. The power densities required for hyperthermic lipolysis are orders of magnitude higher than what any home panel delivers.
If a device manufacturer advertises 1060nm as a feature, treat it as a marketing differentiator rather than an evidence-based advantage — unless they can cite published research using their specific device at that wavelength.
When 1060nm and 1064nm Actually Matter
You Are Considering Clinical Body Contouring
If you are exploring non-invasive fat reduction treatments, 1060nm diode laser (SculpSure) is a clinically validated option with published evidence of modest but measurable fat layer reduction. Consult a qualified practitioner who can assess whether you are a suitable candidate.
You Are Receiving Nd:YAG Laser Treatment
If a dermatologist or surgeon recommends a 1064nm Nd:YAG laser for hair removal, tattoo removal, vascular treatment, or another medical indication, the evidence base is extensive and well-established. This is mainstream medical laser therapy with decades of clinical use.
You Are Comparing Consumer Panel Wavelengths
If you are choosing between consumer PBM panels, the presence or absence of 1060nm should not be a deciding factor. Focus on 660nm (red) and 850nm (near-infrared) — these are the wavelengths with the most clinical support for the applications most home users care about. If a panel also includes 1060nm, it will not cause harm, but do not pay a premium for it based on current evidence.
Summary
The 1060–1064nm wavelength range occupies a distinct niche outside standard photobiomodulation. It does not activate cytochrome c oxidase through the same mechanism as red and near-infrared PBM wavelengths. Its primary clinical relevance is in high-power laser applications: 1060nm diode lasers for non-invasive fat reduction (SculpSure) and 1064nm Nd:YAG lasers for dermatological and surgical procedures.
For home PBM users, 1060nm in a consumer LED panel is not supported by published evidence for any specific therapeutic benefit. The wavelengths that matter for photobiomodulation remain 630–670nm (red) and 810–850nm (near-infrared), where cytochrome c oxidase absorption, tissue penetration, and clinical evidence all converge.
The distinction is important: 1060nm is not a “better” or “more advanced” PBM wavelength. It is a different wavelength with different physics, different biological interactions, and different — primarily clinical, laser-based — applications.
References
- Jacques SL. Optical properties of biological tissues: a review. Phys Med Biol. 2013;58(11):R37-61. PMID: 23208200
- Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life. 2005;57(8):607-615. PMID: 16007521
- Bass LS, Doherty ST. Safety and efficacy of a non-invasive 1060nm diode laser for fat reduction of the flanks. J Cosmet Dermatol. 2018;17(6):985-990. PMID: 29359790
- Katz B, et al. Laser lipolysis: fat reduction by a 1060nm diode laser — histological confirmation and clinical assessment. Aesthetic Surg J. 2017;37(suppl 2):S28-S34. PMID: 28493418
- Decorato JW, et al. Submental fat reduction by ATX-101 (deoxycholic acid) and noninvasive 1060nm laser. Facial Plast Surg Clin North Am. 2017;25(4):491-501. PMID: 28617359
- Peng Q, et al. Lasers in medicine. Rep Prog Phys. 2008;71(5):056701. PMID: 18688659
- Lanigan SW. Incidence of side effects after laser hair removal. J Am Acad Dermatol. 2003;49(5):882-886. PMID: 12654197
- Burq MA, Taqui AM. Frequency of posterior capsule opacification following cataract surgery and YAG laser capsulotomy. J Coll Physicians Surg Pak. 2008;18(12):737-740. PMID: 19086737
- Jackson RF, et al. Low-level laser therapy as a non-invasive approach for body contouring: a randomized, controlled study. Lasers Surg Med. 2009;41(10):799-809. PMID: 19585346
Related topics: 1060nm red light therapy · 1064 nm red light therapy
Find the right device
Compare 20+ red light therapy devices by wavelength, irradiance, and value.